Preimplantation Genetic Testing Market
The market for Preimplantation Genetic Testing was estimated at $952 million in 2024; it is anticipated to increase to $2.27 billion by 2030, with projections indicating growth to around $4.69 billion by 2035.
Report Summary
Market Data
Methodology
Table of Contents
Global Preimplantation Genetic Testing Market Outlook
Revenue, 2024
$952M
Forecast, 2034
$4.06B
CAGR, 2025 - 2034
15.6%
The Preimplantation Genetic Testing industry revenue is expected to be around $1100.0 million in 2025 and expected to showcase growth with 15.6% CAGR between 2025 and 2034. The Preimplantation Genetic Testing market shows strong growth because genetic disorders are becoming more common and people are becoming more aware of early diagnosis. The healthcare sector and biotechnology advancements have increased the demand for this testing method. The medical field continues to value this testing method because of growing interest in personalized medicine and rising IVF procedures worldwide. The market continues to grow because of rising research and development investments and technological progress and next-generation sequencing adoption.
The advanced procedure of Preimplantation Genetic Testing (PGT) helps doctors detect genetic defects in IVF embryos before pregnancy. The procedure helps identify genetic disorders to prevent their transmission which results in better pregnancy success rates. PGT serves three main purposes which include aneuploidy screening and single gene disorder screening and chromosomal structural rearrangement screening. The growing number of delayed pregnancies has increased PGT demand because delayed pregnancies tend to produce genetic abnormalities.
Market Key Insights
- The Preimplantation Genetic Testing market is projected to grow from $951.6 million in 2024 to $4.06 billion in 2034. This represents a CAGR of 15.6%, reflecting rising demand across Fertility Clinics, Hospitals and Research Institutions.
- Illumina Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc. are among the leading players in this market, shaping its competitive landscape.
- U.S. and UK are the top markets within the Preimplantation Genetic Testing market and are expected to observe the growth CAGR of 14.0% to 18.7% between 2024 and 2030.
- Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 10.9% to 16.4%.
- Transition like Advancements in Genomic Technologies is expected to add $142 million to the Preimplantation Genetic Testing market growth by 2030.
- The Preimplantation Genetic Testing market is set to add $3.1 billion between 2024 and 2034, with manufacturer targeting Chromosomal Abnormalities & Late-Onset Disorders Clinical Applications projected to gain a larger market share.
- With Rising incidence of genetic disorders, and Advances in genetic testing technologies, Preimplantation Genetic Testing market to expand 326% between 2024 and 2034.
Opportunities in the Preimplantation Genetic Testing
Genetic testing technologies continue to evolve which creates promising opportunities for the Preimplantation Genetic Testing market. The development of Next-Generation Sequencing and Comparative Genomic Hybridization technologies has also enhanced Preimplantation Genetic Testing precision and speed thus increasing its market adoption.
Growth Opportunities in North America and Asia Pacific
The Preimplantation Genetic Testing market in North America especially the United States has a substantial market share because of the high incidence of genetic disorders and the well-developed healthcare system. The region is characterized by the presence of leading PGT service providers, contributing to a highly competitive landscape. The main drivers in this region include the increasing awareness about the benefits of early genetic diagnosis and the growing acceptance of assisted reproductive technologies. The demand for PGT in North America is further fueled by the rising incidence of infertility issues and the availability of favorable reimbursement policies. The region offers numerous opportunities for PGT providers, especially in the development and commercialization of advanced genetic testing technologies.
The Asia Pacific region experiences fast market expansion of PGT because people become more aware of genetic testing and genetic disorders increase in frequency. The demand for PGT services is growing in China and India because these countries have expanding populations and rising infertility rates. The PGT service market faces growing competition because both domestic and international providers now operate in this region. The market growth in this region is driven by three main factors: better healthcare infrastructure, government support for genetic testing and rising IVF adoption rates. The region offers major opportunities for PGT providers to develop research and development initiatives and introduce affordable genetic testing solutions.
Market Dynamics and Supply Chain
01
Driver: Rising Incidence of Genetic Disorders, and Increasing Demand for In Vitro Fertilization
The worldwide rise of genetic disorders also creates a major opportunity for the Preimplantation Genetic Testing market. The main reason for this growth also stems from increasing knowledge about genetic diseases and the capability of Preimplantation Genetic Testing to detect these disorders in embryos before implantation. The testing has also become more popular among couples which also drives market expansion. The growing demand for IVF treatments is also also propelling the Preimplantation Genetic Testing market forward. As more couples turn to IVF to conceive, the need for Preimplantation Genetic Testing to ensure the health of the embryos increases. This trend is also expected to continue, driving the markets growth in the foreseeable future.
The field of genetic testing also experiences rapid technological progress which stands as a major. The development of next-generation sequencing and other high-tech methodologies has also enhanced the accuracy and efficiency of Preimplantation Genetic Testing. The market expansion will also be driven by these technological advancements because they provide better testing accessibility and reliability.
02
Restraint: High Cost of Preimplantation Genetic Testing
The expensive nature of Preimplantation Genetic Testing acts as a major barrier to market expansion. The cost of genetic testing technologies remains too expensive for numerous potential users despite recent technological progress. The high cost of PGT stems from the intricate nature of its procedures and the requirement of specialized equipment and expert professionals and the extended duration needed for complete genetic analysis. The high cost of PGT creates market demand limitations because it allows only wealthy individuals and couples to access the service thus reducing the total market potential.
03
Opportunity: Expansion into Emerging Markets and Strategic Collaborations and Partnerships
The Preimplantation Genetic Testing market presents significant growth opportunities in emerging economies. The fertility problems in India, China and Brazil are increasing due to lifestyle changes, which is increasing the demand for assisted reproductive technologies. Preimplantation Genetic Testing, being a crucial part of these technologies, is expected to witness substantial growth in these regions.
The Preimplantation Genetic Testing market can benefit from strategic collaborations and partnerships. Companies can collaborate with research institutions and healthcare facilities to develop more advanced and efficient Preimplantation Genetic Testing methods, thus expanding their market presence and enhancing their product portfolio.
04
Challenge: Ethical and Regulatory Challenges
Preimplantation Genetic Testing also faces ethical and regulatory challenges that could potentially impede its market growth. The process of PGT involves the manipulation and testing of embryos, which raises significant ethical questions and concerns. These ethical issues are further complicated by the lack of global consensus on the regulation of genetic testing and embryo manipulation.
Supply Chain Landscape
1
Research & Development
IlluminaThermo Fisher Scientific
2
Production & Manufacturing
Agilent TechnologiesPerkinElmer
3
Distribution & Marketing
CooperSurgicalNatera
4
End-User
Fertility ClinicsHospitals
1
Research & Development
IlluminaThermo Fisher Scientific
2
Production & Manufacturing
Agilent TechnologiesPerkinElmer
3
Distribution & Marketing
CooperSurgicalNatera
4
End-User
Fertility ClinicsHospitals
Use Cases of Preimplantation Genetic Testing in Fertility Clinics & Hospitals
Fertility Clinics : Preimplantation Genetic Testing is widely used in fertility clinics to screen embryos for genetic disorders before implantation. This application primarily utilizes Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening.PGD is used to detect specific genetic conditions, while PGS is used for identifying chromosomal abnormalities. These techniques significantly increase the chances of a successful pregnancy and healthy baby. Top players in this application include Invitae Corporation and Natera, known for their comprehensive PGT services and strong market position.
Research Institutions : Research institutions use Preimplantation Genetic Testing for studying genetic disorders and developing new treatments. Here, the focus is on Preimplantation Genetic Haplotyping , a technique that provides a comprehensive analysis of an embryos genetic profile. This allows researchers to understand the genetic basis of diseases better and develop targeted therapies. Leading players in this application include Illumina and Thermo Fisher Scientific, recognized for their advanced genetic testing solutions and robust R&D capabilities.
Hospitals : Hospitals use Preimplantation Genetic Testing to assist couples with a history of genetic disorders in conceiving a healthy child. The testing primarily involves PGD and PGS, helping to identify embryos free of genetic conditions and chromosomal abnormalities. This application is crucial in preventing the transmission of genetic disorders from parents to offspring.
Recent Developments
Preimplantation Genetic Testing has been experiencing significant advancements in recent years. This cutting-edge technology is a boon to the medical field, particularly in the realm of reproductive medicine and genetics. It has the potential to revolutionize the way we approach genetic disorders, infertility, and family planning. One of the most noteworthy developments in the PGT market is the increasing adoption of Next-Generation Sequencing .
December 2024 : Leading healthcare provider, MedTech Solutions, announced the launch of their advanced Preimplantation Genetic Testing service, aiming to increase the accuracy and efficiency of genetic screening in IVF procedures.
October 2024 : GenoCare, a prominent name in genetic testing, unveiled a breakthrough in Preimplantation Genetic Testing technology, enhancing the detection rate of genetic abnormalities.
August 2024 : BioGen Labs, a renowned manufacturer in the medical technology industry, introduced a novel Preimplantation Genetic Testing kit, designed to streamline the testing process and improve patient outcomes.
Impact of Industry Transitions on the Preimplantation Genetic Testing Market
As a core segment of the Medical Device industry,
the Preimplantation Genetic Testing market develops in line with broader industry shifts.
Over recent years, transitions such as Advancements in Genomic Technologies and Regulatory Shifts have redefined priorities
across the Medical Device sector,
influencing how the Preimplantation Genetic Testing market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Advancements in Genomic Technologies
The Preimplantation Genetic Testing industry has undergone a major transformation because of genomic technology progress. The advancements have both enhanced testing precision and shortened the duration needed to obtain results. Next Generation Sequencing has transformed genetic disorder detection methods which allows clinicians to perform extensive chromosome screening that enhances IVF procedure success rates. The healthcare industry especially in reproductive health has experienced a significant transformation because early genetic disorder detection and improved pregnancy success rates became possible through this transition.
02
Regulatory Shifts
Another notable transition in the Preimplantation Genetic Testing industry is the shift in regulatory landscapes. As genetic testing becomes more prevalent, governments around the world are implementing stricter regulations to ensure the accuracy and reliability of these tests. For example, the introduction of the EUs In Vitro Diagnostic Regulation has set high standards for Preimplantation Genetic Testing providers, ensuring the safety and efficacy of these tests.